a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

被引：1
|
作者：
Maddocks, Kami J. [1 ]
Cohen, Jonathon B. [2 ]
Huang, Ying [1 ]
Christian, Beth A. [3 ,4 ]
Benson, Don M. [1 ]
Jones, Jeffrey [1 ]
Flowers, Christopher [5 ]
Heffner, Leonard T. [6 ]
Jenkins, Cynthia [7 ]
Sexton, Jennfer [7 ]
Neal, Alison [7 ]
Kives, Melissa [2 ]
Blum, Kristie A. [3 ,4 ]
机构：
[1] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[3] James Canc Hosp, Dept Internal Med, Div Hematol, Columbus, OH USA
[4] Ohio State Univ, Solove Res Inst, Columbus, OH USA
[5] Emory Univ, Winship Canc Inst, Dept Bone Marrow & Stem Cell Transplantat, Atlanta, GA USA
[6] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[7] Ohio State Univ, Columbus, OH USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1776.1776
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1776
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Buparlisib/BKM120 PI3 Kinase Therapy in B Cell and T Cell Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL): Identification of Resistance Pathways and Biomarker Discovery
    Beheshti, Afshin
    Coyle, Michael E.
    Dashnamoorthy, Ravi
    Evens, Andrew M.
    BLOOD, 2016, 128 (22)
  • [22] An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)
    Younes, Anas
    Salles, Gilles
    Martinelli, Giovanni
    Bociek, R. Gregory
    Barrigon, Dolores Caballero
    Gonzalez Barca, Eva
    Turgut, Mehmet
    Gerecitano, John F.
    Herbst, Fabian
    Williams, Lisa
    Mukherjee, Nabanita
    Tavorath, Ranjana
    Kim, Won Seog
    BLOOD, 2015, 126 (23)
  • [23] Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    William, Basem M.
    Hohenstein, Maribeth
    Loberiza, Fausto R., Jr.
    Caponetti, Gabriel C.
    Bociek, R. Gregory
    Bierman, Philip
    Armitage, James O.
    Chan, Wing-Chung
    Vose, Julie M.
    BLOOD, 2010, 116 (21) : 131 - 131
  • [24] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
    DeRook, Ian
    Odonnell, Robert T.
    Noble, B.
    Quirch, C.
    Tuscano, Joseph
    BLOOD, 2008, 112 (11) : 1052 - 1052
  • [25] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed Refractory Indolent Non-Hodgkin's Lymphoma (NHL).
    Dutia, Mrinal
    DeRoock, Ian
    Chee, Karen
    O'donnell, Robert
    Quirch, Christine
    Reed-Pease, Christine
    Tuscano, Joseph
    BLOOD, 2009, 114 (22) : 670 - 670
  • [26] Incidence of second primary malignancies (SPM) in relapsed/refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) patients in England
    Miret, M.
    Lee, S.
    Vegni, F. E.
    Hindocha, P.
    Cirneanu, L.
    Lymperopoulou, C.
    Markov, E.
    Hitov, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S780 - S781
  • [27] Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study
    Kamdar, Manali
    Augustson, Bradley
    Rok, Young
    Edwards, James
    Hertzberg, Mark
    Johnston, Amanda
    Kim, Jin Seok
    Kroschinsky, Frank P.
    Smith, Sonali M.
    Stevens, Don A.
    Monnet, Annabelle
    Zhao, Ye
    Nouet, Yann
    Marinova, Viktoriya
    BLOOD, 2020, 136
  • [28] Incidence of second primary malignancies (SPMS) in relapsed/refractory (r/r) b-cell non-hodgkin's lymphoma (NHL) and multiple myeloma (MM) patients in England
    Anderson, Amanda M.
    Miret, Montserrat
    Hindocha, Pooja
    Cirneanu, Lorena
    Lymperopoulou, Christina
    Markov, Emanuil
    Hitov, Svetomir
    Vegni, Ferdinando E.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 512 - 512
  • [29] Phase I study of CC-90011 in patients with advanced solid tumours (STs) and relapsed/refractory non-hodgkin lymphoma (R/R NHL)
    Hollebecque, A.
    de Bono, J. S.
    Salvagni, S.
    Plummer, R.
    Isambert, N.
    Niccoli, P.
    Capdevila, J.
    Curigliano, G.
    Moreno, V.
    De Braud, F. G. M.
    Lopez-Brea, M.
    Martin-Romano, P.
    Baudin, E.
    Arias, M.
    de Alvaro, J.
    Parra-Palau, J.
    Sanchez Perez, T.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] Repeated radioimmunotherapy (RIT) with 131I-rituximab for patients with low grade and aggressive relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)
    Kang, Hye Jin
    Lee, Seung-Sook
    Kim, Kyeong Min
    Lim, Sang Moo
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
12345